Holen Sie sich die Stockscreener-App
4.19
7.19%
0.365
Schlusskurs vom Vortag:
$3.825
Offen:
$3.91
24-Stunden-Volumen:
186.05K
Relative Volume:
1.96
Marktkapitalisierung:
$4.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-10.31M
KGV:
-1.7977
EPS:
-2.3308
Netto-Cashflow:
$-6.32M
1W Leistung:
-0.46%
1M Leistung:
-14.85%
6M Leistung:
-16.71%
1J Leistung:
-64.78%
1-Tages-Spanne:
$3.82
$4.20
1-Wochen-Bereich:
$3.74
$4.23
52-Wochen-Spanne:
$3.2888
$13.20
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Firmenname
Galmed Pharmaceuticals Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare GLMD vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
4.1007 | 4.09M | 0 | -10.31M | -6.32M | -2.3308 |
VRTX
Vertex Pharmaceuticals Inc
|
522.83 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.20 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.32 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.18 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-05-22 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2020-02-04 | Eingeleitet | Craig Hallum | Buy |
| 2020-01-30 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-12-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-08-02 | Bestätigt | Maxim Group | Buy |
| 2018-07-13 | Eingeleitet | Stifel | Buy |
| 2018-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-06-12 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2018-02-14 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-15 | Eingeleitet | ROTH Capital | Buy |
| 2017-08-08 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Bestätigt | Maxim Group | Buy |
| 2016-08-01 | Bestätigt | Maxim Group | Buy |
| 2016-07-06 | Fortgesetzt | ROTH Capital | Buy |
| 2016-03-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-05-06 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
Alle ansehen
Galmed Pharmaceuticals Ltd Aktie (GLMD) Neueste Nachrichten
Galmed Rebrands as EoCene, Secures Nasdaq Compliance and Ends Yorkville Equity Line - TipRanks
EoCene (EOCN) replaces Galmed name and keeps Nasdaq listing - Stock Titan
Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation - PR Newswire
Galmed Pharmaceuticals Regains Nasdaq Bid-Price Compliance, Avoids Delisting Risk - TipRanks
Galmed (NASDAQ: GLMD) regains Nasdaq $1 bid-price compliance - Stock Titan
Galmed Pharmaceuticals Ltd. SEC Filing (Sep 4, 2026) - Stock Titan
Galmed Pharmaceuticals Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Galmed Pharmaceuticals Shareholders Approve All Proposals at September 3 AGM - TipRanks
Shareholders back every Galmed (NASDAQ: GLMD) proposal at September meeting - Stock Titan
Galmed Pharmaceuticals: Q2 Earnings Snapshot - KVUE
Galmed Pharmaceuticals Reports $4.63 Million Net Loss Over First Half of 2026 (NASDAQ: GLMD) - kalkinemedia.com
Galmed Pharmaceuticals Posts Higher R&D Spend and Shrinking Cash in Q2 2026 - TipRanks
Equity deal could dilute Galmed (NASDAQ: GLMD) holders by nearly 40% - Stock Titan
Galmed Pharmaceuticals Adjourns Shareholder Meeting for Lack of Quorum - TipRanks
Reverse split and cash strain leave Galmed (GLMD) below a proposed Nasdaq cutoff - Stock Titan
6-K: Galmed Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
Galmed Pharmaceuticals (GLMD) delays annual meeting to Sept. 3 after low turnout - Stock Titan
Galmed Pharmaceuticals (GLMD) Retreats to $4.17 as Selling Pressure BuildsSynthetic Long - vinanet.vn
Galmed Pharmaceuticals Ltd expected to post a loss of $3.12 a shareEarnings Preview - TradingView
Galmed (GLMD): Slides 5.59% to $4.30 in the Current Update; Immediate View: the Current Price Sits Inside the Supplied Technical Range at the CloseDark Pool Volume - vinanet.vn
Galmed Pharmaceuticals Ltd.: Financial Data Forecasts Estimates and Expectations | GLMD | IL0011313900 - marketscreener.com
Galmed Pharmaceuticals completes 8-for-1 revers... - Pluang
Galmed completes colon tissue assessment study - grafa.com
Galmed completes feasibility study for colon tissue assessment tech By Investing.com - Investing.com Nigeria
Galmed’s Colospan Unit Reports Successful First-in-Human Study for New Colorectal Surgery Platform - TipRanks
Colospan completes successful study on new colo... - Pluang
Galmed completes feasibility study for colon tissue assessment tech - Investing.com
Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology - PR Newswire
Galmed Reports Aramchol–Xtandi Combo Boosts Prostate Cancer Cell Death in Pre-Clinical Study - TipRanks
Galmed reports pre-clinical data on Aramchol-enzalutamide combo - Investing.com
Galmed reports pre-clinical data on Aramchol-enzalutamide combo By Investing.com - Investing.com UK
Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models - Yahoo Finance Singapore
Galmed Pharmaceuticals to Enact 1-for-8 Reverse Share Split Effective August 19, 2026 - TipRanks
Galmed Pharmaceuticals (GLMD) to implement 1-for-8 reverse share split in August 2026 - Stock Titan
Galmed Pharmaceuticals (GLMD) Slips 6.1% to $0.56 as Selling Pressure IntensifiesIchimoku Kumo Twist - Vinanet
Galmed Pharmaceuticals (GLMD) Holds at $0.60 as Micro-Cap Biotech Trades Between Key LevelsPrice Action Signals - dars.gov.et
Galmed Pharmaceuticals Ltd (GLMD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Galmed Pharmaceuticals (GLMD) Rises 5.4% to $0.62, Approaching Key ResistanceOpening Range Breakout - vinanet.vn
GLMD Q1 2026 Earnings: Surprise Profit Beats Estimates as Shares Gain 5.4%Earnings Deceleration Risk - Vinanet
Galmed Pharmaceuticals Wins Nasdaq Extension to Regain $1 Bid Price Compliance - TipRanks
Galmed Pharmaceuticals (NASDAQ: GLMD) granted new deadline to meet $1 bid rule - Stock Titan
Galmed Pharmaceuticals Ltd. (GLMD) Q1 2026 Earnings: Surprise Profit Driven by Expense Management and Non-Operating GainsEarnings Power Value - dars.gov.et
Galmed Pharmaceuticals Drops Yissum License to Sharpen Focus on Colospan and Aramchol - TipRanks
Galmed advances Parkinson’s drug formulation with higher CNS exposure - Investing.com
Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market - PR Newswire
Galmed Pharmaceuticals Ltd (GLMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Galmed Pharmaceuticals Ltd - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GLMD|Galmed Pharmaceuticals Ltd|Price:0.602|Chg%:-0.004 - TradingKey
GLMD|Galmed Pharmaceuticals Ltd|Price:0.523|Chg%:-0.008 - TradingKey
Galmed Pharmaceuticals (GLMD) Slides 5.4%: Testing Key Support After Bearish MoveSymmetrical Triangle - vinanet.vn
Finanzdaten der Galmed Pharmaceuticals Ltd-Aktie (GLMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):